Metastatic Cancer Treatment Market Revenue Analysis & Region and Country Forecast To 2028 | Emergen Research

The increasing incidence of metastatic cancer is one of the significant factors influencing the market growth.                           

According to a recent analysis by Emergen Research, the Metastatic Cancer Treatment Market worldwide is expected to reach USD 111.16 billion by 2027. Due to the rising cancer prevalence, there is a significant demand for metastatic cancer treatment systems. The illness has a sizable negative influence on societal and economic development in the US and around the world, and it greatly adds to the disease’s financial burden. In 2020, it is predicted that 1,806,590 new cancer cases will be diagnosed in the US, and 606,520 people will pass away from the disease.

One of the illnesses that has a big impact on society all over the world is cancer. The National Institute of Cancer estimates that 1,806,590 Americans will be diagnosed with cancer in 2020, and 606,520 will pass away from it. The American Institute of Cancer Research estimates that there were 18,100 active cases of cancer worldwide in 2020. Furthermore, the World Health Organization (WHO) reported that cancer was a factor in 10,000 fatalities, or 1 in 6 deaths worldwide. Lung cancer, breast cancer, colon cancer, rectum cancer, and prostate cancer are the most prevalent cancer kinds. Every year, 400,000 youngsters develop the illness. Helicobacter pylori, the hepatitis B virus, the human papillomavirus (HPV), the hepatitis C virus, and the Epstein-Barr virus were among the carcinogenic illnesses that contributed to 13% of cancer cases worldwide in 2018.

According to estimates from the International Agency for Research on Cancer (IARC), there will be 29.5 million new instances of cancer worldwide by 2040, up from 16.4 million in 2018. In addition, the American Society of Clinical Oncology estimates that 290,560 Americans (287,850 women and 2,710 males) will receive an invasive breast cancer diagnosis in 2021. It is widely acknowledged that breast cancer in women is the most common type of cancer in the world, surpassing lung cancer. In 2020, 2,261,419 women were estimated to have received a breast cancer diagnosis.

One fact hasn’t altered among all the observations made about cancer in the US throughout the years: metastatic cancer causes up to 90% of all cancer deaths annually. These figures have inspired medical professionals and researchers to develop fresh approaches to treating metastasis, which happens when cancer spreads outside of its original site. In the US, 6% of women had metastatic breast cancer at the time of their initial diagnosis. The growth of the metastatic cancer drug market is being driven by this increase in the occurrence of metastatic cancer.

Key participants include Bayer AG, Johnson & Johnson, AstraZeneca PLC, Pfizer Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Amgen Inc., Merck & Co. Inc., AbbVie Inc., and Novartis AG, among others.

Some of the Report’s Important Highlights

Systems Oncology, LLC and Bayer agreed to a licence agreement for ERSOTM, a pre-clinical treatment for metastatic breast cancer, in September 2020. (ER-positive).

With 2 million new cases in 2018, lung cancer ranked third among women’s cancers and is a frequent malignancy in men. 2018 had the greatest sickness rates in the top three nations of Hungary, Serbia, and New Caledonia (France).

Specialty clinics have the necessary radiotherapy equipment, devices, and staff on hand to help with illness diagnosis and choosing the best course of action for treating metastatic cancer.

Due to a high adoption of cutting-edge treatment technologies, an increase in cancer incidence, an established healthcare infrastructure, and the implementation of numerous initiatives to raise awareness of the disease, the metastatic cancer treatment market in the North American region held the largest market share in 2019.

Emergen Research has segmented the global metastatic cancer treatment market on the basis of treatment type, application, end-users, and region:

Treatment Type Outlook (Revenue, USD Billion; 2017-2027)

  • Chemotherapy
  • Hormone Therapy
  • Immunotherapy
  • Others

Application Outlook (Revenue, USD Billion; 2017-2027)

  • Breast Cancer
  • Lung Cancer
  • Melanoma
  • Prostate Cancer
  • Colorectal Cancer
  • Others

End Users Outlook (Revenue, USD Billion; 2017-2027)

  • Hospital
  • Clinics
  • Research Institutes
  • Others

For Detailed Information: Click Here